Targets › GMCSF
1 program from 1 company in 3 trials: 3 Phase 2; Oncology; next expected readout Dec 2026.
Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. (UniProt, P04141)
Open in Phaseline: the race on GMCSF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Talimogene Laherparepvec ICP34.5- and ICP47-deleted herpes simplex virus 1 (HSV-1) expressing human GM-CSF | GMCSF | Phase 2 | Advanced Melanoma; Leiomyosarcoma; Anaplastic Large Cell Lymphoma, ALK-Negative | Dec 2026 |
Advanced Melanoma (1) Leiomyosarcoma (1) Anaplastic Large Cell Lymphoma, ALK-Negative (1)
mixed (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.